<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082628</url>
  </required_header>
  <id_info>
    <org_study_id>24380</org_study_id>
    <nct_id>NCT00082628</nct_id>
  </id_info>
  <brief_title>Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients</brief_title>
  <official_title>A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine if Serostim® 4 mg administered daily for
      12 weeks as treatment for the abnormal fat accumulation and distribution associated with
      HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT,
      measured by CT scan) more effectively than placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 28, 2004</start_date>
  <completion_date type="Actual">September 28, 2005</completion_date>
  <primary_completion_date type="Actual">September 28, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Absolute area of VAT was measured by cross-sectional computed tomography (CT) scan at the level of the L4-5 inter-vertebral disk. CT scanning was to be used to assess the cross sectional area of abdominal fat and its distribution between the visceral and subcutaneous compartments, as measured at L4-L5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Period I: Change From Baseline in Trunk Fat at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Changes in trunk fat was measured as changes in mass (kg) on Dual-Energy X-Ray Absorptiometry (DXA) Scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Body image distress was assessed on a scale ranging from 0 to 100, where 0 = Extremely Upsetting and 100 = Extremely Encouraging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Lipid profile data was analyzed for Non-HDL Cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I</measure>
    <time_frame>Week 36</time_frame>
    <description>Failure rate based on VAT was assessed by CT scan at L4-L5. The failure rate was defined as the percentage of subjects who regained &gt;50% of their VAT lost in Treatment Period I. This outcome was to be assessed for subjects who received Serostim® 4 mg in Period I.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">326</enrollment>
  <condition>HIV Infections</condition>
  <condition>Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>Period I: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period I: Serostim® 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period II: Serostim® 4 mg to Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive placebo matched to Serostim® on alternate days for 24 weeks in Period II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period II: Serostim® 4 mg to Serostim® 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive Serostim® 2 mg on alternate days for 24 weeks in Period II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period II: Placebo to Placebo/Serostim® 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects who will be initially randomized to Placebo arm in Period I continue receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to serostim® as subcutaneous injection.</description>
    <arm_group_label>Period I: Placebo</arm_group_label>
    <arm_group_label>Period II: Placebo to Placebo/Serostim® 4 mg</arm_group_label>
    <arm_group_label>Period II: Serostim® 4 mg to Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serostim® 4 mg</intervention_name>
    <description>Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.</description>
    <arm_group_label>Period I: Serostim® 4 mg</arm_group_label>
    <arm_group_label>Period II: Placebo to Placebo/Serostim® 4 mg</arm_group_label>
    <other_name>recombinant human growth hormone (r-hGH)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serostim® 2 mg</intervention_name>
    <description>Serostim® 2 mg as subcutaneous injection on alternate days.</description>
    <arm_group_label>Period II: Serostim® 4 mg to Serostim® 2 mg</arm_group_label>
    <other_name>recombinant human growth hormone (r-hGH)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have written laboratory documentation of an HIV infection by one of the following
             methods:

               -  Detectable viral load measured by polymerase chain reaction (PCR) amplification,
                  branched chain DNA (bDNA) signal amplification or the presence of p24 antigen.

               -  Presence of HIV antibodies confirmed by either Western blot or immunofluorescence
                  assay.

             Written laboratory documentation of an HIV infection must be obtained prior to
             randomization. In the absence of documented historical confirmation, an assay of HIV
             antibodies will be included in the Screening Laboratory Panel. Results will be
             confirmed with a Western Blot.

          2. Have evidence of excess abdominal adipose deposition when measured by the
             anthropometric methodology, using the following cut off values:

               -  Men: Waist circumference &gt;88.2 cm AND waist: hip ratio &gt;= 0.95.

               -  Women: Waist circumference &gt;75.3 cm AND waist: hip ratio &gt;= 0.9.

          3. Are taking antiretroviral medication(s) which is (are) approved or is (are) available
             under a Treatment IND. The regimen must have remained stable for 30 days prior to
             study entry. Subjects must also agree not to discontinue or to change their regimen
             for the duration of the study except as judged medically necessary.

          4. Have parameter values less than the following limits (using results from the central
             laboratory):

               -  AST, ALT, and amylase &lt;= 3 times the upper limit of normal (Screening).

               -  Fasting triglycerides &lt;= 1,000 mg/dL (Screening).

               -  Fasting glucose &lt;110 mg/dL (Screening).

               -  Two-hour (120 minute) glucose &lt;140 mg/dL (Screening).

          5. Weight &gt;= 36 kg (79.3 lb)

          6. Be between 18 and 60 years of age (inclusive) unless local law dictates different
             limits.

          7. Sufficiently literate in English to be able to comprehend and complete the Quality of
             Life Questionnaire.

          8. Willing and able to comply with the protocol for the duration of the study.

          9. Have voluntarily provided written informed consent (with subject authorization under
             HIPAA), prior to performing any study-related procedure that is not part of normal
             medical care, and with the understanding that the subject may withdraw consent at any
             time without prejudice to future medical care.

         10. Female subjects must:

               1. Be post menopausal (&gt;= 1 year) or surgically sterilized (i.e., have undergone
                  tubal ligation or hysterectomy)

                  or

               2. Use a contraceptive method for the duration of the study such as:

                    -  Hormonal contraceptive

                    -  Intra uterine device

                    -  Diaphragm with spermicide, or condom with spermicide.

                  And

               3. Must be neither pregnant nor breast feeding.

               4. Confirmation that female subjects of childbearing potential are not pregnant must
                  be established by a negative beta-hCG serum pregnancy test during the 14-day
                  screening period prior to Study Day 1. If the beta-hCG serum pregnancy test is
                  performed more than 7 days prior to Study Day 1, a urine pregnancy test must be
                  performed by the site laboratory on Study Day 1 to confirm a negative test
                  result.

        Exclusion Criteria:

          1. Have an active AIDS-defining opportunistic complication (OC) as defined by the CDC or
             have had an untreated or suspected serious systemic infection, or have had a
             persistent fever &gt;= 101°F (38.3°C) during the 30 days prior to study entry.

          2. Any active or past history of malignancy, except for localized cutaneous Kaposi's
             sarcoma (fewer than 10 lesions, none of which are larger than 2 cm, and not on active
             therapy). Such exceptions must be confirmed in writing by the Serono Study Director.

          3. Have a CNS mass or active CNS process associated with neurological findings.

          4. Have unstable or untreated hypertension, defined as &gt;= 140/90 mm Hg at the time of the
             Screening Visit, and/or have initiated or changed antihypertensive therapy in the 30
             days prior to Study Day 1.

          5. Have an acute critical illness treated in an intensive care unit, e.g., due to
             complications following open heart or abdominal surgery, multiple accidental trauma,
             or acute respiratory failure.

          6. Have a recent history of sleep apnea or intermittent upper respiratory obstruction.

          7. Have any condition, which interferes with informed consent or protocol compliance
             including, but not limited to, active substance abuse and/or dementia.

          8. Are unable to comply with the Concomitant Therapy restrictions including:

               -  therapy for obesity including therapy with anorexigenic or fat reducing drugs

               -  anti-diabetic or insulin sensitizing medications

               -  systemic glucocorticoids

               -  systemic chemotherapy, interferon or radiation therapy treatment

               -  androgenic agents including, but not limited to testosterone, nandrolone,
                  oxandrolone, oxymetholone, etc. (testosterone replacement therapy for
                  hypogonadism is the exception to this exclusion and will be allowed if started &gt;
                  30 days prior to Study Day 1)

               -  progestational agents, unless used for oral contraception or post-menopausal
                  hormone replacement therapy

               -  appetite stimulants

               -  investigational agents, unless approved in advance by the study medical director.
                  Specifically, experimental antiretroviral agents are disallowed, unless available
                  under a treatment IND or expanded access program (30 days).

               -  Liposuction or other elective plastic surgery

               -  AIDS wasting therapy or prior growth hormone treatment other than study drug (for
                  12 months prior to the screening visit)

          9. Have ever been diagnosed with any of the following conditions:

               -  Pancreatitis

               -  Carpal tunnel syndrome (unless resolved by surgical release)

               -  Diabetes mellitus

               -  Angina pectoris

               -  Coronary artery disease

               -  Any disorder associated with moderate to severe edema (e.g., ascites, nephrotic
                  syndrome, congestive heart failure, lymphedema).

         10. Allergy or hypersensitivity to growth hormone.

         11. Are participating in any other clinical studies.

        In order to participate in this trial a subject must meet all of the inclusion and
        exclusion criteria specified above. Requests for protocol exceptions/exemptions must come
        from a participating, fully initiated site at which a prospective patient has consented to
        undergo screening. Exceptions/exemptions are only allowed by the Trial Director. There is
        no program in place to allow drug for a single patient IND, or for an expanded access
        protocol. This statement holds true for both children and adults.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama/Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE CLINIC - UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1401 N. Palm Canyon</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trials Unit Div of Infectious and Immunologic Diseases</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD - AntiViral Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco - Div. of Endocrinology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Institute for Research and Education, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Ctr Research &amp; Education Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Alliance</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1640 Rhode Island Avenue, N.W.</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office Of Dr Gary Richmond</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3661 South Miami Avenue</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Resources</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Associates</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative of New England</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative Of New England</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell Universtiy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Women's Interagency HIV Study</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clincial research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IDP Research</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Daniel Coulston, M.D.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Program</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.serostim.com</url>
    <description>Full FDA approved prescribing information can be found here</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/17592343?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=1</url>
    <description>Link to PubMed</description>
  </link>
  <link>
    <url>http://journals.lww.com/jaids/Fulltext/2007/07010/Recombinant_Human_Growth_Hormone_to_Treat.6.aspx</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>May 13, 2004</study_first_submitted>
  <study_first_submitted_qc>May 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2004</study_first_posted>
  <results_first_submitted>October 2, 2017</results_first_submitted>
  <results_first_submitted_qc>October 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2018</results_first_posted>
  <last_update_submitted>October 2, 2017</last_update_submitted>
  <last_update_submitted_qc>October 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth hormone</keyword>
  <keyword>Serostim®</keyword>
  <keyword>Human Adipose Redistribution Syndrome</keyword>
  <keyword>Human Immunodeficiency Virus lipodystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Period I: Placebo</title>
          <description>Subjects received placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Period I: Serostim® 4 mg</title>
          <description>Subjects received Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Period II: Serostim® 4 mg to Placebo</title>
          <description>All subjects who were initially randomized to Serostim® 4 mg arm in Period I and received placebo matched to Serostim® on alternate days for 24 weeks in Period II.</description>
        </group>
        <group group_id="P4">
          <title>Period II: Serostim® 4 mg to Serostim® 2 mg</title>
          <description>All subjects who were initially randomized to Serostim® 4 mg arm in Period I and received Serostim® 2 mg on alternate days for 24 weeks in Period II.</description>
        </group>
        <group group_id="P5">
          <title>Period II: Placebo to Placebo/Serostim® 4 mg</title>
          <description>All subjects who were initially randomized to Placebo arm in Period I continued receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period I (Week 1 to Week 12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="245"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="185"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subjects Did Not Receive Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects Without Post-Baseline Assessmen</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects Did Not Complete Week 12</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not continue to Period II</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period II: Week 12 to Week 36</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="92"/>
                <participants group_id="P5" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects Did Not Complete Week 36</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The modified ITT Population (ITT) for Period I was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement.</population>
      <group_list>
        <group group_id="B1">
          <title>Period I: Placebo</title>
          <description>Subjects received placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Period I: Serostim® 4 mg</title>
          <description>Subjects received Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="243"/>
            <count group_id="B3" value="322"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="7.5"/>
                    <measurement group_id="B2" value="44.5" spread="7.0"/>
                    <measurement group_id="B3" value="44.8" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12</title>
        <description>Absolute area of VAT was measured by cross-sectional computed tomography (CT) scan at the level of the L4-5 inter-vertebral disk. CT scanning was to be used to assess the cross sectional area of abdominal fat and its distribution between the visceral and subcutaneous compartments, as measured at L4-L5.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The modified ITT Population was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement in treatment period I. Here &quot;Overall Number of Participants Analyzed&quot; signifies those subjects who were evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Period I: Placebo</title>
            <description>Subjects received placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period I: Serostim® 4 mg</title>
            <description>Subjects received Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12</title>
          <description>Absolute area of VAT was measured by cross-sectional computed tomography (CT) scan at the level of the L4-5 inter-vertebral disk. CT scanning was to be used to assess the cross sectional area of abdominal fat and its distribution between the visceral and subcutaneous compartments, as measured at L4-L5.</description>
          <population>The modified ITT Population was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement in treatment period I. Here &quot;Overall Number of Participants Analyzed&quot; signifies those subjects who were evaluable for this outcome.</population>
          <units>Square Centimeter (cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="34.5"/>
                    <measurement group_id="O2" value="-32.6" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Nonparametric ANCOVA Model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Period I: Change From Baseline in Trunk Fat at Week 12</title>
        <description>Changes in trunk fat was measured as changes in mass (kg) on Dual-Energy X-Ray Absorptiometry (DXA) Scan.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The modified ITT Population was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement in treatment period I. Here &quot;Overall Number of Participants Analyzed&quot; signifies those subjects who were evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Period I: Placebo</title>
            <description>Subjects received placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period I: Serostim® 4 mg</title>
            <description>Subjects received Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Period I: Change From Baseline in Trunk Fat at Week 12</title>
          <description>Changes in trunk fat was measured as changes in mass (kg) on Dual-Energy X-Ray Absorptiometry (DXA) Scan.</description>
          <population>The modified ITT Population was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement in treatment period I. Here &quot;Overall Number of Participants Analyzed&quot; signifies those subjects who were evaluable for this outcome.</population>
          <units>Kilogram (Kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.3"/>
                    <measurement group_id="O2" value="-2.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12</title>
        <description>Body image distress was assessed on a scale ranging from 0 to 100, where 0 = Extremely Upsetting and 100 = Extremely Encouraging.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The modified ITT Population was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement in treatment period I.</population>
        <group_list>
          <group group_id="O1">
            <title>Period I: Placebo</title>
            <description>Subjects received placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period I: Serostim® 4 mg</title>
            <description>Subjects received Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12</title>
          <description>Body image distress was assessed on a scale ranging from 0 to 100, where 0 = Extremely Upsetting and 100 = Extremely Encouraging.</description>
          <population>The modified ITT Population was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement in treatment period I.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="1.42"/>
                    <measurement group_id="O2" value="0.10" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12</title>
        <description>Lipid profile data was analyzed for Non-HDL Cholesterol.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The modified ITT Population was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement in treatment period I. Here &quot;Overall Number of Participants Analyzed&quot; signifies those subjects who were evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Period I: Placebo</title>
            <description>Subjects received placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Period I: Serostim® 4 mg</title>
            <description>Subjects received Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12</title>
          <description>Lipid profile data was analyzed for Non-HDL Cholesterol.</description>
          <population>The modified ITT Population was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement in treatment period I. Here &quot;Overall Number of Participants Analyzed&quot; signifies those subjects who were evaluable for this outcome.</population>
          <units>milligram/deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="28.1"/>
                    <measurement group_id="O2" value="-13.0" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I</title>
        <description>Failure rate based on VAT was assessed by CT scan at L4-L5. The failure rate was defined as the percentage of subjects who regained &gt;50% of their VAT lost in Treatment Period I. This outcome was to be assessed for subjects who received Serostim® 4 mg in Period I.</description>
        <time_frame>Week 36</time_frame>
        <population>The modified ITT Population for treatment period II was defined as subjects who were re-randomized into Weeks 12 to 36 of the study and who had at least one post-Week 12 efficacy evaluation. Here &quot;Overall Number of Participants Analyzed&quot; signifies those subjects who were evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Period II: Serostim® 4 mg to Placebo</title>
            <description>All subjects who were initially randomized to Serostim® 4 mg arm in Period I and received placebo matched to Serostim® on alternate days for 24 weeks in Period II.</description>
          </group>
          <group group_id="O2">
            <title>Period II: Serostim® 4 mg to Serostim® 2 mg</title>
            <description>All subjects who were initially randomized to Serostim® 4 mg arm in Period I and received Serostim® 2 mg on alternate days for 24 weeks in Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I</title>
          <description>Failure rate based on VAT was assessed by CT scan at L4-L5. The failure rate was defined as the percentage of subjects who regained &gt;50% of their VAT lost in Treatment Period I. This outcome was to be assessed for subjects who received Serostim® 4 mg in Period I.</description>
          <population>The modified ITT Population for treatment period II was defined as subjects who were re-randomized into Weeks 12 to 36 of the study and who had at least one post-Week 12 efficacy evaluation. Here &quot;Overall Number of Participants Analyzed&quot; signifies those subjects who were evaluable for this outcome.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                    <measurement group_id="O2" value="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety analyses were performed on subjects who received at least one injection of study drug (Serostim® or placebo).</desc>
      <group_list>
        <group group_id="E1">
          <title>Period I: Placebo (Week 1 to 12)</title>
          <description>Subjects received placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Period I: Serostim® 4 mg (Week 1 to 12)</title>
          <description>Subjects received serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Period II: Serostim® 4 mg to Placebo (Week 12 to 36)</title>
          <description>All subjects who were initially randomized to Serostim® 4 mg arm in Period I and received placebo matched to Serostim® on alternate days for 24 weeks in Period II.</description>
        </group>
        <group group_id="E4">
          <title>Period II: Serostim® 4 mg to Serostim® 2 mg (Week 12 to 36)</title>
          <description>All subjects who were initially randomized to Serostim® 4 mg arm in Period I and received Serostim® 2 mg on alternate days for 24 weeks in Period II.</description>
        </group>
        <group group_id="E5">
          <title>Period II: Placebo to Placebo (Week 12 to Week 24)</title>
          <description>All subjects who were initially randomized to Placebo arm in Period I continued receiving placebo matched to Serostim® on alternate days for 12 weeks in Period II.</description>
        </group>
        <group group_id="E6">
          <title>Period II: Placebo to Serostim® 4 mg (Week 24 to 36)</title>
          <description>All subjects who were initially randomized to Placebo arm in Period I and received Serostim® 4 mg daily 12 weeks in Period II.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (7.0)">Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pancreatic insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (7.0)">Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (7.0)">Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (7.0)">Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="244" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="73" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Healthcare, a business of Merck KGaA, Darmstadt, Germany</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

